The China National Medical Products Association (NMPA) has approved Shingrix for the prevention of shingles. Shingrix has been approved for the prevention of virus in adults aged 18 years and over who are at increased risk of shingles due to immunodeficiency or immunosuppression. Shingles is caused… Read More
GSK presented six abstracts at the Alzheimer’s Association International Conference (AAIC), including real-world data which shows an association between recombinant zoster vaccine (RZV) and potential reduced risk of dementia. Tony Wood, Chief Scientific Officer, said: “Building on our expertise in immunology and inflammation, we’re using advanced technology… Read More
New evidence indicates that a new shingles vaccine is more protective against dementia compared to the previous shingles vaccine, which was also reported to reduce dementia rates. It is also more protective than vaccines against other infections. A study of more… Read More
New data have shown that GSK’s Shingrix provides at least 10 years of protection against shingles in adults aged 50 years and over. In the primary endpoint, the interim data demonstrated overall efficacy of greater than 80% over the follow-up period of approximately six to 10 years after initial vaccination. Read More
